Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 2Head & Neck 1Breast 1

Conditions

Squamous Cell Carcinoma of Head and Neck 2Stomach Neoplasms 1Head and Neck Neoplasms 1Esophageal Squamous Cell Carcinoma 1Breast Neoplasms 1

Interventions

pembrolizumab 30Nivolumab 11atezolizumab 8Docetaxel 8Cisplatin 7Carboplatin 7Gemcitabine 6fludarabine 5Trastuzumab 5Paclitaxel 5Ipilimumab 5Fluorouracil 5Cyclophosphamide 5spartalizumab 4cemiplimab 4avelumab 4Polymerase Chain Reaction 4Cetuximab 4Capecitabine 4Bevacizumab 4130-nm albumin-bound paclitaxel 4aldesleukin 3Taxes 3Oxaliplatin 3Magnetic Resonance Spectroscopy 3Leucovorin 3Interleukin-2 3Gene Expression Profiling 3Drug Therapy 3Biopsy 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Stomach Neoplasms × elgemtumab × Head & Neck × Clear all
NCT01598077 2020-12-19

A Phase I Study of LJM716 in Squamous Cell Carcinoma of Head and Neck, or HER2+ Breast Cancer or Gastric Cancer

Novartis

Phase 1 Completed
54 enrolled
BreastGastrointestinalHead & Neck

Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Breast Neoplasms, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡